Boehringer Ingelheim Atrovent
Executive Summary
Dissemination of journal reprint on "Effectiveness and Safety of Intranasal Ipratropium Bromide in Common Colds" is promotion of an unapproved use, FDA contends in March 25 letter. The reprint promotes Atrovent for relief of sneezing associated with common colds, FDA says, when labeling "specifically excludes sneezing from the list of common cold symptoms relieved" by Atrovent nasal spray